Anti-VEGF therapy also showed a higher quality of life in MMD patients supported with moderate-certainty evidence, and was suggested to be significantly effective in improving visual acuity and reducing central macular thickness compared to PDT with moderate to low certainty of evidence (Table 4). This evidence concerns the gene VEGFA and multiminicore myopathy.